Index -
P/E 26.61
EPS (ttm) 2.91
Insider Own 35.15%
Shs Outstand 145.16M
Perf Week -11.58%
Market Cap 10.66B
Forward P/E 22.84
EPS next Y 3.39
Insider Trans -0.12%
Shs Float 89.28M
Perf Month -16.70%
Income 427.20M
PEG 1.88
EPS next Q 0.47
Inst Own 83.03%
Short Float 3.72%
Perf Quarter 7.65%
Sales 2.96B
P/S 3.60
EPS this Y 5.09%
Inst Trans -11.09%
Short Ratio 4.14
Perf Half Y 28.70%
Book/sh 9.49
P/B 8.16
EPS next Y 25.06%
ROA 10.87%
Short Interest 3.32M
Perf Year -6.53%
Cash/sh 3.55
P/C 21.83
EPS next 5Y 14.15%
ROE 34.30%
52W Range 53.79 - 94.86
Perf YTD 5.39%
Dividend Est. 0.20 (0.26%)
P/FCF 43.84
EPS past 5Y 20.48%
ROI 16.35%
52W High -18.36%
Beta 1.22
Dividend TTM 0.20 (0.26%)
Quick Ratio 0.99
Sales past 5Y 9.74%
Gross Margin 51.17%
52W Low 43.97%
ATR (14) 2.35
Dividend Ex-Date Feb 29, 2024
Current Ratio 1.80
EPS Y/Y TTM 46.17%
Oper. Margin 16.27%
RSI (14) 22.29
Volatility 3.46% 2.25%
Employees 9707
Debt/Eq 1.00
Sales Y/Y TTM 17.14%
Profit Margin 14.41%
Recom 2.00
Target Price 86.90
Option/Short Yes / Yes
LT Debt/Eq 0.90
EPS Q/Q 113.71%
Payout 6.89%
Rel Volume 0.90
Prev Close 78.56
Sales Surprise 5.83%
EPS Surprise 2.44%
Sales Q/Q 20.62%
Earnings Feb 13 BMO
Avg Volume 801.85K
Price 77.44
SMA20 -13.68%
SMA50 -10.94%
SMA200 7.99%
Trades
Volume 622,184
Change -1.43%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-14-24 Upgrade
JP Morgan
Neutral → Overweight
$60 → $90
Dec-19-23 Initiated
Wells Fargo
Equal Weight
$72
Dec-13-23 Initiated
Wolfe Research
Outperform
$80
Oct-21-22 Initiated
UBS
Buy
$70
Aug-22-22 Upgrade
Citigroup
Neutral → Buy
$70 → $80
Oct-15-21 Resumed
Cowen
Market Perform
$68
Jun-15-21 Upgrade
Cleveland Research
Neutral → Buy
Feb-05-21 Downgrade
Wells Fargo
Overweight → Equal Weight
$50 → $55
Dec-02-20 Initiated
Goldman
Sell
$50
Nov-16-20 Upgrade
Wolfe Research
Underperform → Peer Perform
May-01-20 Downgrade
Cleveland Research
Buy → Neutral
Apr-02-20 Downgrade
Wolfe Research
Peer Perform → Underperform
$27
Apr-01-20 Downgrade
Needham
Strong Buy → Hold
Mar-26-20 Upgrade
Barclays
Equal Weight → Overweight
$48
Jan-08-20 Initiated
Wells Fargo
Overweight
$60
Jan-07-20 Initiated
Citigroup
Buy
$52
Nov-15-19 Initiated
Stifel
Hold
Sep-26-19 Upgrade
BofA/Merrill
Neutral → Buy
$52
Jul-15-19 Upgrade
Goldman
Sell → Neutral
$32 → $48
Jun-24-19 Reiterated
Needham
Strong Buy
$46 → $57
Show Previous Ratings
Apr-18-24 06:46AM
Apr-09-24 09:02AM
Apr-08-24 07:00AM
07:00AM
Apr-04-24 08:11AM
07:00AM
Loading…
Apr-01-24 07:00AM
Mar-22-24 09:48AM
Mar-14-24 11:30AM
09:08AM
Mar-12-24 07:51AM
Mar-11-24 07:00AM
Mar-07-24 07:00AM
Mar-06-24 05:01PM
Mar-05-24 08:23AM
Mar-01-24 08:39AM
07:00AM
Loading…
Feb-28-24 07:00AM
Feb-26-24 05:00PM
05:00PM
10:52AM
10:42AM
09:37AM
Feb-17-24 02:00PM
Feb-16-24 04:05PM
Feb-15-24 09:07AM
Feb-14-24 10:03AM
02:06AM
(Thomson Reuters StreetEvents)
Feb-13-24 09:30AM
08:45AM
07:51AM
07:49AM
(Associated Press Finance)
07:00AM
Loading…
07:00AM
Feb-12-24 12:10PM
09:14AM
Feb-07-24 07:00AM
Feb-06-24 04:05PM
07:00AM
Feb-05-24 07:00AM
Feb-01-24 10:00AM
Jan-30-24 01:36PM
(Investor's Business Daily)
Jan-29-24 10:41AM
Jan-25-24 07:00AM
Jan-23-24 08:00AM
Jan-16-24 11:22AM
Jan-11-24 12:10PM
Jan-05-24 08:05AM
Jan-04-24 08:00AM
08:00AM
Jan-03-24 04:35PM
07:00AM
Dec-27-23 07:34AM
Dec-20-23 11:32AM
Dec-19-23 09:41AM
Nov-28-23 07:50AM
Nov-27-23 09:15AM
Nov-20-23 04:15PM
Nov-07-23 09:00AM
Nov-06-23 07:18AM
Nov-04-23 01:25PM
Nov-02-23 09:18AM
07:33AM
(Associated Press Finance)
07:00AM
Oct-27-23 11:07AM
Oct-26-23 10:02AM
Oct-20-23 12:10PM
Oct-12-23 08:13AM
Oct-05-23 08:32AM
Oct-04-23 08:47AM
07:00AM
Oct-03-23 07:00AM
Oct-02-23 04:05PM
Sep-19-23 01:09PM
Sep-18-23 07:00AM
Sep-15-23 04:06AM
Sep-12-23 11:48AM
Sep-08-23 07:54AM
Sep-07-23 07:00AM
Sep-06-23 07:43AM
Sep-05-23 04:02PM
Aug-24-23 04:05PM
06:21AM
(American City Business Journals)
Aug-18-23 11:09AM
Aug-17-23 09:00AM
Aug-16-23 04:05PM
Aug-14-23 07:00AM
Aug-13-23 09:35AM
Aug-04-23 09:45AM
12:51AM
Aug-03-23 11:40PM
(Thomson Reuters StreetEvents)
11:30AM
08:35AM
07:24AM
07:00AM
Aug-02-23 08:05AM
Jul-31-23 08:51AM
Jul-29-23 10:06AM
Jul-25-23 04:44PM
Jul-11-23 08:52AM
Jul-10-23 07:00AM
Jul-04-23 10:31AM
Jul-03-23 08:15AM
Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI Nano segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Gunther Laukien in 1960 and is headquartered in Billerica, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Requardt Hermann Fritz Director Mar 04 '24 Option Exercise 22.05 15,000 330,750 38,147 Mar 06 04:05 PM Requardt Hermann Fritz Director Mar 04 '24 Sale 90.06 15,000 1,350,898 23,147 Mar 06 04:05 PM Busse Falko PRESIDENT, BIOSPIN GROUP Feb 28 '24 Option Exercise 26.28 28,122 739,156 60,981 Mar 01 04:05 PM Busse Falko PRESIDENT, BIOSPIN GROUP Feb 28 '24 Sale 85.48 28,122 2,403,890 32,859 Mar 01 04:05 PM Prause Burkhard PRES. & CEO, BRUKER BEST Feb 22 '24 Option Exercise 43.17 5,450 235,292 32,384 Feb 26 04:02 PM Prause Burkhard PRES. & CEO, BRUKER BEST Feb 22 '24 Sale 83.30 15,319 1,276,073 17,065 Feb 26 04:02 PM LINTON WILLIAM A Director Dec 05 '23 Option Exercise 19.07 10,000 190,700 33,048 Dec 07 04:01 PM LAUKIEN FRANK H PRESIDENT & CEO Oct 26 '23 Option Exercise 46.14 59,523 2,746,689 38,327,911 Oct 30 04:11 PM LAUKIEN FRANK H PRESIDENT & CEO Aug 08 '23 Option Exercise 47.85 44,150 2,112,578 38,255,291 Aug 10 05:09 PM LAUKIEN FRANK H PRESIDENT & CEO Aug 08 '23 Sale 64.81 37,947 2,459,345 38,217,344 Aug 10 05:09 PM LAUKIEN FRANK H PRESIDENT & CEO Jul 27 '23 Option Exercise 37.42 68,454 2,561,549 38,249,088 Jul 31 04:10 PM Herman Gerald N EXECUTIVE VICE PRESIDENT, CFO Jun 16 '23 Sale 75.42 14,242 1,074,132 36,462 Jun 20 04:31 PM Kastner Marc A Director May 19 '23 Sale 75.22 11,146 838,402 8,051 May 22 04:15 PM LAUKIEN FRANK H PRESIDENT & CEO May 16 '23 Sale 73.11 14,625 1,069,174 38,180,634 May 17 04:17 PM LAUKIEN FRANK H PRESIDENT & CEO May 15 '23 Sale 72.75 185,375 13,485,866 38,262,287 May 17 04:17 PM LAUKIEN FRANK H PRESIDENT & CEO May 09 '23 Sale 75.20 110,982 8,345,410 38,100,011 May 10 04:18 PM LAUKIEN FRANK H PRESIDENT & CEO May 08 '23 Sale 77.05 89,018 6,859,094 38,210,993 May 10 04:18 PM LAUKIEN FRANK H PRESIDENT & CEO May 03 '23 Sale 79.21 16,435 1,301,816 38,352,034 May 04 04:11 PM LAUKIEN FRANK H PRESIDENT & CEO May 02 '23 Sale 77.98 100,770 7,858,030 38,161,517 May 03 04:15 PM LAUKIEN FRANK H PRESIDENT & CEO May 01 '23 Sale 78.75 82,795 6,519,841 38,262,287 May 03 04:15 PM LAUKIEN FRANK H PRESIDENT & CEO Apr 25 '23 Sale 78.86 51,770 4,082,702 38,262,287 Apr 26 04:17 PM LAUKIEN FRANK H PRESIDENT & CEO Apr 24 '23 Sale 81.02 148,230 12,009,461 38,349,926 Apr 26 04:17 PM
Index RUT
P/E -
EPS (ttm) -8.37
Insider Own 3.79%
Shs Outstand 75.71M
Perf Week -5.90%
Market Cap 1.90B
Forward P/E -
EPS next Y -4.92
Insider Trans -1.33%
Shs Float 73.71M
Perf Month -15.76%
Income -626.60M
PEG -
EPS next Q -1.28
Inst Own 110.35%
Short Float 13.92%
Perf Quarter -8.13%
Sales 937.82M
P/S 2.03
EPS this Y 26.53%
Inst Trans 1.90%
Short Ratio 11.27
Perf Half Y 21.27%
Book/sh -10.81
P/B -
EPS next Y 20.02%
ROA -34.73%
Short Interest 10.26M
Perf Year -53.27%
Cash/sh 11.44
P/C 2.17
EPS next 5Y -9.51%
ROE -
52W Range 17.53 - 59.84
Perf YTD -9.80%
Dividend Est. -
P/FCF -
EPS past 5Y -24.94%
ROI -
52W High -58.46%
Beta 0.71
Dividend TTM -
Quick Ratio 1.97
Sales past 5Y 29.08%
Gross Margin 69.28%
52W Low 41.81%
ATR (14) 1.35
Dividend Ex-Date -
Current Ratio 2.02
EPS Y/Y TTM -7.52%
Oper. Margin -37.26%
RSI (14) 34.88
Volatility 4.72% 4.77%
Employees 995
Debt/Eq -
Sales Y/Y TTM 34.20%
Profit Margin -66.81%
Recom 2.93
Target Price 29.17
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 12.28%
Payout -
Rel Volume 0.69
Prev Close 24.69
Sales Surprise -2.51%
EPS Surprise -1390.59%
Sales Q/Q 83.41%
Earnings Apr 25 AMC
Avg Volume 910.31K
Price 24.86
SMA20 -9.84%
SMA50 -11.18%
SMA200 -14.68%
Trades
Volume 543,714
Change 0.69%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-19-23 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$28
Dec-08-23 Initiated
Wells Fargo
Overweight
$37
Oct-30-23 Upgrade
Oppenheimer
Perform → Outperform
$165
Oct-27-23 Downgrade
Citigroup
Neutral → Sell
$29 → $17
Oct-06-23 Downgrade
Truist
Buy → Hold
$45 → $25
Sep-18-23 Downgrade
Citigroup
Buy → Neutral
$55 → $28
Sep-15-23 Downgrade
Raymond James
Outperform → Underperform
Mar-17-23 Initiated
SVB Securities
Market Perform
$48
Dec-14-22 Initiated
Goldman
Sell
$35
Sep-12-22 Initiated
Jefferies
Buy
$62
Sep-09-22 Initiated
Morgan Stanley
Equal-Weight
$54
Sep-01-22 Initiated
Citigroup
Buy
$70
Apr-04-22 Resumed
Cantor Fitzgerald
Overweight
$64 → $63
Oct-18-21 Downgrade
BofA Securities
Neutral → Underperform
$38
Apr-26-21 Resumed
Credit Suisse
Neutral
$54
Mar-29-21 Upgrade
RBC Capital Mkts
Underperform → Sector Perform
$47
Feb-12-21 Downgrade
BofA Securities
Buy → Neutral
Jan-05-21 Upgrade
Citigroup
Neutral → Buy
$67 → $85
Nov-30-20 Downgrade
RBC Capital Mkts
Sector Perform → Underperform
$45
Oct-30-20 Downgrade
Citigroup
Buy → Neutral
Show Previous Ratings
Apr-18-24 10:01AM
Apr-11-24 08:00AM
Mar-28-24 08:30AM
Mar-25-24 10:00AM
Mar-20-24 02:00PM
07:30AM
Loading…
Mar-19-24 07:30AM
Mar-02-24 08:56AM
Mar-01-24 06:51AM
(Thomson Reuters StreetEvents) +13.34%
Feb-29-24 06:00PM
05:20PM
04:33PM
04:30PM
(Associated Press Finance)
04:05PM
Feb-27-24 05:20PM
Feb-26-24 09:16AM
04:30PM
Loading…
Feb-22-24 04:30PM
Feb-15-24 08:00AM
Feb-13-24 10:00AM
Feb-11-24 01:45AM
Jan-26-24 04:06PM
(Investor's Business Daily)
11:45AM
(Investor's Business Daily)
10:18AM
(Investor's Business Daily)
Jan-25-24 04:51PM
04:20PM
04:05PM
Jan-24-24 07:02PM
Jan-12-24 01:02AM
Jan-08-24 09:26AM
Jan-03-24 08:00AM
Dec-20-23 09:41AM
05:01PM
Loading…
Dec-15-23 05:01PM
Dec-14-23 04:30PM
Dec-05-23 04:15PM
Nov-14-23 03:58PM
Nov-03-23 04:30PM
Oct-30-23 09:03AM
Oct-27-23 11:22AM
(Thomson Reuters StreetEvents) -22.71%
10:01AM
08:33AM
07:15AM
02:38AM
Oct-26-23 07:30PM
06:10PM
05:30PM
04:25PM
(Associated Press Finance)
04:05PM
Oct-24-23 10:00AM
Oct-19-23 07:02PM
10:01AM
08:00AM
Oct-16-23 04:30PM
Oct-11-23 08:07AM
Oct-06-23 09:42AM
Sep-29-23 11:18AM
Sep-28-23 05:15PM
04:42PM
04:30PM
Sep-25-23 03:18AM
Sep-20-23 04:00AM
Sep-19-23 06:46AM
Sep-15-23 04:04PM
(Investor's Business Daily) -29.77%
09:28AM
(Investor's Business Daily)
06:00AM
Sep-12-23 08:00AM
Sep-07-23 07:33PM
08:00AM
08:00AM
Aug-30-23 08:00AM
Aug-28-23 08:00AM
Aug-25-23 01:38PM
Aug-04-23 01:24PM
Aug-03-23 09:30PM
05:25PM
04:14PM
04:01PM
Jul-21-23 09:30AM
Jul-20-23 08:00AM
Jul-19-23 04:30PM
Jul-18-23 04:30PM
Jul-17-23 04:30PM
Jul-11-23 12:00PM
Jun-30-23 10:18AM
Jun-29-23 04:30PM
09:18AM
Jun-28-23 07:41AM
Jun-21-23 04:24PM
07:31AM
07:12AM
07:00AM
Jun-15-23 04:30PM
Jun-02-23 08:00AM
May-31-23 06:05AM
May-25-23 10:32AM
May-24-23 04:06PM
(Investor's Business Daily) -19.62%
12:48PM
12:33PM
May-23-23 05:36PM
(Investor's Business Daily)
04:07PM
04:05PM
May-18-23 12:59PM
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Golden Lee Scott EVP & CHIEF MEDICAL OFFICER Apr 02 '24 Sale 28.37 526 14,923 59,988 Apr 04 05:16 PM Boulding Mark Elliott EXEC. VP AND CLO Jan 30 '24 Sale 27.25 794 21,637 71,189 Feb 01 04:17 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 30 '24 Sale 27.25 618 16,841 61,202 Feb 01 04:18 PM Pauwels Eric CHIEF BUSINESS OFFICER Jan 30 '24 Sale 27.25 366 9,974 44,181 Feb 01 04:16 PM Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER Jan 30 '24 Sale 27.25 318 8,666 35,528 Feb 01 04:15 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 30 '24 Sale 27.25 28 763 3,706 Feb 01 04:18 PM Jacobson Allan Steven Director Jan 22 '24 Option Exercise 27.05 10,000 270,500 22,348 Jan 24 04:30 PM Jacobson Allan Steven Director Jan 22 '24 Sale 27.38 10,000 273,804 12,348 Jan 24 04:30 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Jan 09 '24 Sale 29.01 5,443 157,928 160,475 Jan 10 04:08 PM Pauwels Eric CHIEF BUSINESS OFFICER Jan 09 '24 Sale 29.01 2,065 59,916 44,547 Jan 10 04:09 PM Boulding Mark Elliott EXEC. VP AND CLO Jan 09 '24 Sale 29.01 1,938 56,231 71,983 Jan 10 04:04 PM Utter Christine Marie SVP, FINANCE & CAO Jan 09 '24 Sale 29.01 1,653 47,961 35,846 Jan 10 04:11 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 09 '24 Sale 29.01 1,521 44,132 61,820 Jan 10 04:03 PM Golden Lee Scott CHIEF MEDICAL OFFICER Jan 09 '24 Sale 29.01 1,225 35,543 37,914 Jan 10 04:06 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 09 '24 Sale 29.01 100 2,901 3,734 Jan 10 04:03 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Jan 08 '24 Sale 28.64 2,237 64,068 165,918 Jan 10 04:08 PM Pauwels Eric CHIEF BUSINESS OFFICER Jan 08 '24 Sale 28.64 1,569 44,937 46,612 Jan 10 04:09 PM Boulding Mark Elliott EXEC. VP AND CLO Jan 08 '24 Sale 28.64 1,457 41,729 73,921 Jan 10 04:04 PM SCHMERTZLER MICHAEL Director Jan 08 '24 Sale 27.81 1,500 41,715 115,266 Jan 10 04:10 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 08 '24 Sale 28.64 1,236 35,399 63,341 Jan 10 04:03 PM Utter Christine Marie SVP, FINANCE & CAO Jan 08 '24 Sale 28.64 1,188 34,025 37,499 Jan 10 04:11 PM Golden Lee Scott CHIEF MEDICAL OFFICER Jan 08 '24 Sale 28.64 775 22,196 39,139 Jan 10 04:06 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 08 '24 Sale 28.64 53 1,518 3,834 Jan 10 04:03 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Jan 05 '24 Sale 27.15 10,107 274,393 168,155 Jan 09 04:29 PM Gravier Pierre CHIEF FINANCIAL OFFICER Dec 12 '23 Buy 25.81 7,700 198,736 33,700 Dec 14 04:38 PM Young Alethia Director Sep 06 '23 Option Exercise 27.85 11,666 324,898 16,067 Sep 08 04:02 PM Young Alethia Director Sep 06 '23 Sale 39.86 11,666 464,972 9,067 Sep 08 04:02 PM SCHMERTZLER MICHAEL Director Jun 07 '23 Sale 44.86 1,000 44,860 116,766 Jun 09 04:03 PM Reeve Emma Director May 23 '23 Option Exercise 33.38 2,652 88,520 8,602 May 24 04:12 PM Reeve Emma Director May 23 '23 Sale 59.53 2,652 157,885 7,200 May 24 04:12 PM Reeve Emma Director May 22 '23 Option Exercise 33.37 7,116 237,484 11,148 May 24 04:12 PM Reeve Emma Director May 22 '23 Sale 59.53 7,116 423,630 7,200 May 24 04:12 PM Pauwels Eric CHIEF BUSINESS OFFICER May 22 '23 Sale 59.01 2,013 118,791 47,553 May 23 04:05 PM Pauwels Eric CHIEF BUSINESS OFFICER May 19 '23 Sale 58.96 6,403 377,491 49,566 May 23 04:05 PM Pauwels Eric CHIEF BUSINESS OFFICER May 18 '23 Sale 58.71 788 46,267 55,969 May 19 04:04 PM Pauwels Eric CHIEF BUSINESS OFFICER May 17 '23 Sale 58.50 8,048 470,822 56,757 May 19 04:04 PM Jacobson Allan Steven Director May 11 '23 Option Exercise 10.85 23,000 249,550 35,348 May 12 04:08 PM Jacobson Allan Steven Director May 11 '23 Sale 55.08 23,000 1,266,930 12,348 May 12 04:08 PM Utter Christine Marie SVP, FINANCE & CAO Apr 21 '23 Option Exercise 33.02 4,692 154,930 42,380 Apr 25 04:09 PM Utter Christine Marie SVP, FINANCE & CAO Apr 21 '23 Sale 55.06 4,692 258,326 38,059 Apr 25 04:09 PM Reeve Emma Director Apr 21 '23 Sale 55.05 4,328 238,258 7,200 Apr 25 04:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite